University of Bristol
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From University of Bristol
Finance Watch: Olema IPO Raises $209m To Advance OPI-1250 For Breast Cancer
Olema launched this year’s 75th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
Venture Funding Deals: Tenaya's $92m, Nuvation's $275m Lead October Rounds
Former Medivation CEO David Hung launched stealthy oncology start-up Nuvation with $275m in series A venture capital, while Tenaya's series B brought in $92m for small molecules as well as cell and gene therapies to treat cardiovascular diseases.
Deals Shaping The Medical Industry, May 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Supplies – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2016.
Deals Of The Week: Vertex/GSK, Vertex/Janssen, Boehringer Ingelheim/Ensemble
Disparate events including Hurricane Sandy, extended-release generics, drug compounding and biopharma deal-making each highlighted just how important a challenge quality has become in the industry.
- Academic and Research Institutions
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.